Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists.

3D structure of CysLT2 receptor was constructed by using homology modeling and molecular simulations. The binding pocket of CysLT2 receptor and the proposition of the interaction mode between CysLT2 and HAMI3379 were identified. A series of dicarboxylated chalcones was then virtually evaluated through molecular docking studies. A total of six compounds 13a-f with preferable scores was further synthesized and tested for CysLT2 antagonistic activities by determination of the cytosolic free Ca(2+) levels in HEK293 cells. Compounds 13e and 13f exhibited potent and selective CysLT2 antagonistic activities with IC50 values being 7.5 and 0.25 μM, respectively.

[1]  K. Austen,et al.  Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Choon-Sik Park,et al.  Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild‐to‐moderate asthma: A 4 week randomized multicentre controlled trial , 2001, Respirology.

[3]  C. Venkatachalam,et al.  LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.

[4]  Francesca Deflorian,et al.  Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. , 2003, Chemical communications.

[5]  Management of Asthma with Zafirlukast , 2012, Drugs.

[6]  Marcus Elstner,et al.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.

[7]  American Thoracic Society, San Diego, California, USA , 2006 .

[8]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[9]  E. Mayatepek,et al.  Leukotrienes: Biosynthesis, Metabolism, and Pathophysiologic Significance , 1995, Pediatric Research.

[10]  P. Kolkhof,et al.  Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor , 2010, British journal of pharmacology.

[11]  J. Drazen,et al.  Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.

[12]  Y. Masuho,et al.  The Molecular Characterization and Tissue Distribution of the Human Cysteinyl Leukotriene CysLT2 Receptor , 2000 .

[13]  W. Im,et al.  Automated Builder and Database of Protein/Membrane Complexes for Molecular Dynamics Simulations , 2007, PloS one.

[14]  K. Jacobson,et al.  Modelling the P2Y purinoceptor using rhodopsin as template. , 1995, Drug design and discovery.

[15]  Piercarlo Fantucci,et al.  GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors , 2008, BMC Bioinformatics.

[16]  Klaus Schulten,et al.  Molecular dynamics investigation of primary photoinduced events in the activation of rhodopsin. , 2002, Biophysical journal.

[17]  D P Tieleman,et al.  A computer perspective of membranes: molecular dynamics studies of lipid bilayer systems. , 1997, Biochimica et biophysica acta.

[18]  K. Chung,et al.  Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. , 1995, The European respiratory journal.

[19]  Y. Masuho,et al.  The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. , 2000, Biochemical and biophysical research communications.

[20]  S. Véronneau,et al.  Cysteinyl‐leukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  David E. Gloriam,et al.  GPCRdb: an information system for G protein-coupled receptors , 2015, Nucleic Acids Res..

[22]  Daniel Gunzelmann,et al.  Synthesis and modification of a functionalized 3D open-framework structure with MIL-53 topology. , 2009, Inorganic chemistry.

[23]  Claudia Martini,et al.  In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases , 2011, J. Comput. Aided Mol. Des..

[24]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[25]  Guo-liang Yu,et al.  Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice , 2005, Brain Research.

[26]  Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety. , 2007, Bioorganic & medicinal chemistry letters.

[27]  V. Capra.  Molecular and functional aspects of human cysteinyl leukotriene receptors. , 2004, Pharmacological research.

[28]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.

[29]  K. Jacobson,et al.  A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. , 1997, Molecular pharmacology.

[30]  H. Claesson,et al.  Asthma and leukotrienes: antileukotrienes as novel anti‐asthmatic drugs , 1999, Journal of internal medicine.

[31]  D. Major,et al.  Molecular recognition in purinergic receptors. 2. Diastereoselectivity of the h-P2Y1-receptor. , 2004, Journal of medicinal chemistry.

[32]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[33]  K. Jacobson,et al.  Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. , 2005, Journal of medicinal chemistry.

[34]  D. Major,et al.  Molecular recognition in purinergic receptors. 1. A comprehensive computational study of the h-P2Y1-receptor. , 2004, Journal of medicinal chemistry.

[35]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[36]  M. Bäck.  Functional characteristics of cysteinyl-leukotriene receptor subtypes. , 2002, Life sciences.

[37]  M. Parmentier,et al.  Nucleotide sequence of a human cannabinoid receptor cDNA. , 1990, Nucleic acids research.

[38]  H. Timmerman,et al.  Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists. , 1997, Journal of medicinal chemistry.

[39]  H. Khorana,et al.  Assembly of functional rhodopsin requires a disulfide bond between cysteine residues 110 and 187. , 1990, The Journal of biological chemistry.

[40]  Jilly F. Evans,et al.  Characterization of the Human Cysteinyl Leukotriene 2 Receptor* , 2000, The Journal of Biological Chemistry.

[41]  Bo Yang,et al.  Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists. , 2010, Bioorganic & medicinal chemistry.

[42]  H. Berendsen,et al.  Molecular dynamics simulations of a fully hydrated dipalmitoylphosphatidylcholine bilayer with different macroscopic boundary conditions and parameters , 1996 .

[43]  B. Nair,et al.  A Study of the Interaction of Cr(III) Complexes and Their Selective Binding with B-DNA: A Molecular Modeling Approach , 2002, Journal of biomolecular structure & dynamics.

[44]  M. Parenti,et al.  CysLT1 signal transduction in differentiated U937 cells involves the activation of the small GTP-binding protein Ras. , 2004, Biochemical pharmacology.

[45]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[46]  J. T. Turner,et al.  Site-directed Mutagenesis of P2U Purinoceptors , 1995, The Journal of Biological Chemistry.